PubMed Health⌕ Search

Biomedical subjects

Bing-he Xu

Publications and source records attributed to Bing-he Xu.

11 recordsLinked to original sources
PubMed2006

[Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms].

OBJECTIVE: It has been proposed that genetic polymorphisms in apoptosis-related genes might be associated with sensitivity of cancer cells to platinum-based chemotherapy. This study examined the relationship between p53 and p73 genetic polymorphisms and the response to platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 165 patients with advanced NSCLC treated with platinum-based chemotherapy were genotyped for the p53 codon 72 Pro-->Arg and p73 exon 2 G4C14-->A4T14 polymorphisms using PCR-RFLP and ARMS-PCR assays. Clinical response to the chemotherapy was obtained after 2 to 3 cycles. The adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional logistic regression model. All statistical tests were two-sided. RESULTS: The p53 Pro allele carriers had higher response rate than non-carriers (OR = 2.46; 95% CI = 1.11 - 5.45). A higher response rate was also observed for the p73 G4C14/A4T14 or A4T14/A4T14 genotype, compared with the G4C14/G4C14 genotype (OR = 2.22; 95% CI = 1.14 - 4.30). When these two polymorphisms were combined to be analyzed, it was found that the response rate in those carrying the wild-type genotypes at both genes was only 7.7%, whereas the response rates in patients carrying 1, 2, or more than 2 variant alleles of p53 and p73 were 34.8%, 42.2% and 40.7%, respectively. CONCLUSION: Those results suggest that p53 and p73 polymorphisms may be associated with clinical responsiveness to platinum-based chemotherapy in advanced NSCLC.

Adult↗
PubMed2006

[XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].

OBJECTIVE: DNA repair system plays an important role in tumor sensitivity to platinum-based chemotherapy. The purpose of this study was to examine the association between polymorphisms in XRCC1 and XPD, which are involved in DNA repair, and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). METHODS: XRCC1 Arg194Trp and XPD Lys751Gln were genotyped by PCR-RFLP method in 200 patients with advanced NSCLC who received platinum-based chemotherapy. Unconditional logistic regression model was used to analyze the association between genetic polymorphisms and clinical responses. RESULTS: The overall response rate (CR + PR) was 36.0%, including 1 CR, 72 PR, 94 SD and 34 PD. The XRCC1 194Trp allele carriers had higher response rate than the subjects with the Arg/Arg genotype (adjusted OR, 2.48; 95% CI, 1.36 - 4.51, P = 0.003). However, the XPD Lys751Gln polymorphism was not found to be associated with the platinum-based chemotherapy. These two genetic polymorphisms may have some interaction in the drug sensitivity, the P value for the trend was significant (P = 0.004). CONCLUSION: Those results suggest that the XRCC1 Arg194Trp and XPD Lys751Gln genetic polymorphisms may be associated with clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer.

Adult↗
PubMed2006

[Clinical features and prognosis in breast cancer patients over 70 years of age].

OBJECTIVE: To investigate the clinical characteristics and prognostic factors in breast cancer patients over 70 years of age. METHODS: From 1980 to 2003, 280 female breast cancer patients over 70 years old were treated and the data were retrospectively reviewed. The clinical features including age, comorbidity, initial symptom, tumor size and location, pathological type, lymph node status, hormonal receptor status, treatment approaches and overall survival were analyzed. RESULTS: These 280 patients accounted for 2.9% of all breast cancer patients registered in our institution during the same period. Presentation of breast lump as initial symptom accounted for 92.5% of the patients. The median time from the presentation of initial symptom to initial diagnosis was 4 months. Major pathological type was invasive ductal carcinoma (74.3%). Estrogen or progesterone receptor was found to be positive in 72.9% by immunohistochemical staining. 165 patients (58.9%) had comorbidity such as coronary heart disease, hypertension, diabetes, etc. 256 patients underwent surgery consisting of 162 modified mastectomies, 46 mastectomies, 38 lumpectomies, 7 lumpectomies plus lymph node dissection, 2 lymph node resection and 1 with unavailable surgery record. The cumulative 5- and 10-year overall survival was 69.9% and 40.6%, respectively. Factors affecting the prognosis were tumor size, lymph node status, pathological stage, vascular invasion and endocrine therapy by univariate analysis. The lymph node status and vascular invasion were found to be two independent prognostic factors affecting significantly the prognosis by multivariate analysis. CONCLUSION: Female breast cancer patients over 70 years of age exhibit distinctive clinical and pathological characteristics. Surgery and endocrine therapy are important to achieve good clinical outcome. Lymph node status and vascular invasion are two independent prognostic factors.

Aged↗
PubMed2005

[Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].

OBJECTIVE: Nucleotide excision repair has been shown to have great impact on the sensitivity of tumors to platinum-based chemotherapy. This study was to examine the association between genetic polymorphisms in XPC and XPD, two important components in nucleotide excision repair system, and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. METHODS: Patients (n = 151) treated with platinum-based chemotherapy were genotyped for the AT dinucleotide insertion or deletion in intron 9 of XPC or Lys751Gln polymorphism in XPD. Clinical response to chemotherapy was obtained after 2 to 3 cycles. The adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional logistic regression model and adjusted for sex, age, clinical stage, and regime of chemotherapy. RESULTS: The overall response rate to the chemotherapy (CR + PR) was 35.1%, with 1 CR, 52 PR, 75 SD, and 23 PD. It was found that patients with the XPC LL genotype had significantly higher response rate than patients with the XPC SS genotype (adjusted OR = 3.19, 95% CI = 1.11 - 9.17; P = 0.031). However, no association was found between the XPD Lys751Gln polymorphism and response to the chemotherapy. In addition, these two polymorphisms seemed to have synergic effect, with the OR being 2.90 (95% CI = 1.07 - 7.86) for patients carrying the XPC LL and XPD Lys/Lys genotypes compared with those carrying the XPC SS or SL and XPD Lys/Lys genotypes. CONCLUSION: These results suggest that genetic polymorphisms in nucleotide excision repair might be associated with clinical response to platinum-based chemotherapy.

Adult↗
PubMed2005

[Characteristics and prognostic factors of postoperative chemotherapy for female breast cancer patients under 30 years of age: a report of 129 patients].

OBJECTIVE: To analyze the clinical characteristics, survival and prognosis of breast cancer patients under 30 years of age. METHODS: 129 breast cancer patients under 30 years treated from Jan 1980 to May 2000 were retrospectively reviewed. Clinical features, survival and prognostic factors were analyzed by SPSS 10.0 statistic software. RESULTS: Breast cancer patients under 30 years accounted for 2.6% of all breast cancers in our hospital. The overall 5- and 10-year survival rates were 61.5% and 46.7%, respectively. For patients with tumor < or = 3 cm or > 3 cm, the 10-year survival rates were 65.5% and 27.4% (P < 0.01). For those with number of positive axillary lymph nodes 0, 1-3, or > or = 4, the 10-year survival rates were 79.5%, 40.9% or 31.4% (P < 0.01). For patients who had been treated with or without tamoxifen, the 10-year survival rates were 63.7% and 45% (P < 0.01). For those complicated with pregnancy and lactation which was found in 24.8% of such patients, the 10-year survival rate was 44.3%. In the multivariate analysis, independent prognostic factors that might improve the overall survival were tumor size, axillary metastatic status and tamoxifen treatment. CONCLUSION: Breast cancer patients aged 30 years and younger may have good prognosis if multimodality treatment is given. Tumor size, axillary metastatic status and tamoxifen treatment are independent prognostic factors. Prognosis of patients, either complicated with pregnancy and lactation or not, is quite similar if the clinical stage is the same and if being treated by the combined therapy.

Adolescent↗
PubMed2004

Correlation between serum HER-2 oncoprotein and patients with breast cancer.

OBJECTIVE: To detect serum HER-2 oncoprotein levels in patients with operable and metastatic breast cancers, and to study the correlations between serum HER-2 level and lymph node status as well as other clinical parameters. METHODS: A total of 120 women were studied consisting of 10 healthy volunteers, 31 benign breast disease, 53 operable breast cancer, and 26 metastatic breast cancer patients. The levels of serum HER-2 were measured using an enzyme-liked immunosorbent assay (ELISA). RESULTS: The mean serum HER-2 levels were 9.6 +/- 1.5 ng/mL in healthy volunteers, 11.9 +/- 1.6 ng/mL in benign breast disease, 13.2 +/- 4.2 ng/mL in operable breast cancer, and 30.5 +/- 30.8 ng/mL in metastatic breast cancer patients. The former is much lower than the latter three (P = 0.02, 0.001, 0.03, respectively). If using 15 ng/mL as a normal baseline, elevated serum HER-2 levels were observed in none of the healthy volunteers as well as patients with benign disease, but in 18.9% (10/53) operable breast cancer patients and 61.5% (16/26) metastatic patients. In patients with operable breast cancer, there was a positive correlation between serum concentrations of HER-2 and the size of primary tumor (P < 0.05), whereas there was no correlation between serum concentration and axillary lymph node or estrogen receptor status. In patients with metastatic disease, there was no correlation with site of metastases (P > 0.05). CONCLUSION: Serum HER-2 level was strongly correlated with tumor loads and clinical stages, thus acting as a promising predictor of cancer recurrence in breast cancer patients.

Biomarkers, Tumor↗
PubMed2003

[Recombinant human interleukin-11 in the prevention of chemotherapy-induced thrombocytopenia].

OBJECTIVE: To evaluate the efficacy and toxicity of domestic recombinant human interleukin-11 (rhIL-11) in the prevention of chemotherapy-induced thrombocytopenia. METHODS: A randomized, self-crossover and placebo-controlled trial was conducted, with rhIL-11 and placebo classified randomly as drug A and drug B. Patients were randomly assigned to group AB or group BA. 25 microg/kg body weight of drug A or drug B was administered subcutaneously once daily starting 24 hours after chemotherapy and continued for 7 to 14 days or until the platelet count reached > or = 300 x 10(9)/L. RESULTS: 118 patients were evaluable in the efficacy study. When compared with the placebo treated cycle, the results showed that rhIL-11 was able to significantly increase the platelet count at the nadir and d21 after chemotherapy, with a increase of 60.7% and 86.1% (both P < 0.001). The mean duration of thrombocytopenia (< 100 x 10(9)/L) in rhIL-11 treated cycle was 1.0 +/- 2.0 days as compared to 6.9 +/- 5.3 days in placebo treated cycle. The side effects were ache (24.6%), swelling (16.1%) and knurl (11.9%) at the injection site, hyperaemia of conjunctiva (16.1%), edema (8.5%), palpitation (6.8%) and fatigue (5.1%). CONCLUSION: rhIL-11, possessing significant thrompoietic activity, significantly increases the likelihood of avoiding chemotherapy-induced thrombocytopenia and shorten the duration of thrombocytopenia. Its side effects are mild and manageable.

Adolescent↗
PubMed2003

[Oral combination chemotherapy of 5'-deoxy-5-fluorouridine (furtulon) and cyclophosphamide for advanced breast cancer].

OBJECTIVE: To evaluate the efficacy and safety of the oral combination chemotherapy of furtulon (FTL) and cyclophosphamide (CTX) for advanced breast cancer (ABC). METHODS: From Jun 2000 to Jun 2002, eighty-three patients with ABC were treated with the two oral drugs as combined chemotherapy. The mean number of cycles was 5, median number of cycles was 6 (range 2-6). RESULTS: The overall response rate was 45.8%, The median time to progression was 6 months. The treatment was well tolerated, with related Grade 3 clinical adverse effect being only nausea and vomiting in 2 patients (2.4%) and mild hematologic toxicities. CONCLUSION: Oral combined chemotherapy of FTL and CTX, being convenient and safe, is effective for patients with advanced breast cancer.

Administration, Oral↗
PubMed2003

[Serum her-2/neu level and related factors in patients with breast cancer].

OBJECTIVE: To detect serum her-2/neu level in patients with breast cancer of different stages and its relationship with tissue her-2/neu overexpression as well as other factors. METHODS: A total of 120 women were alloted in this study, including 10 healthy volunteers, 31 breast benign disease patients, 53 primary breast cancer and 26 metastatic breast cancer patients. The level of serum her-2/neu was detected with enzyme-linked immunosorbent assay (ELISA). RESULTS: Elevated serum her-2/neu levels were observed in 0/10 healthy volunteers, 0/31 patients with benign tumor and 10/53 (18.9%) operable breast cancer patients. Serum concentration of soluble her-2/neu was correlated with tumor size (P < 0.05), but not with axillary lymph nodes nor estrogen receptor status. In patients with metastatic disease, soluble her-2/neu serum level was elevated in 61.5% (16/26) of patients, which was not correlated with the site of metastasis (P > 0.05). CONCLUSION: Serum her-2/neu level is correlated with tumor malignancy, stage and cancer load. It could be helpful in directing the treatment of recurrent or metastatic breast cancer.

Breast Neoplasms↗
PubMed2002

[Inflammatory breast cancer: 38 cases clinical report].

BACKGROUND & OBJECTIVE: Inflammatory breast cancer (IBC) is a special form of rapidly progressive breast cancer with poor prognosis. The purpose of this study was to investigate the clinical characters, treatment, and prognosis of inflammatory breast cancer. METHODS: Thirty-eight patients with inflammatory breast cancer who were diagnosed and treated from March 20, 1970 to December 21, 2001 in our hospital were analyzed retrospectively. RESULTS: All IBC patients presented clinically with an erythematous or swollen and tender breast, no fever. The mean age of 38 patients was 45 years old. Twenty-four patients were in stage III b and 14 in stage IV. Eighteen patients received local treatment (radiotherapy or surgery) firstly and 20 patients underwent chemotherapy firstly. Median survival was 17 months. The 1 year and the 5 year survival rates were 57.7% and 14.0%, respectively. The administration of chemotherapy first improved the outcome of IBC. Earlier stage showed more favorable prognosis. CONCLUSIONS: Combination therapy with chemotherapy first was an effective treatment for IBC.

Adult↗